Business
Doseology Appoints Larry Latowsky as Executive Chairman of the Board of Directors
Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70) ("Doseology" or the "Company") is pleased to announce the appointment of Larry Latowsky as a director and the Executive Chairman of its Board of Directors, effective February 18, 2026.
About this update from Doseology Sciences, Inc.
[{"type":"text","content":"VANCOUVER, BC, Feb. 20, 2026 /PRNewswire/ -- Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70) ("Doseology" or the "Company") is pleased to announce the appointment of Larry Latowsky as a director and the Executive Chairman of its Board of Directors, effective February 18, 2026.","length":316,"tagName":"p"},{"type":"image","alt":"Doseology Sciences Inc. Logo (PRNewsfoto/Doseology Sciences Inc.)","displaySize":"","headline":null,"caption":"Doseology Sciences Inc. Logo (PRNewsfoto/Doseology Sciences Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":209,"url":"https://media.zenfs.com/en/prnewswire.com/5074e94047bc8f0af85685e5b26bfc79"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fHVuo5O.lP0m9Gr5pP9R9A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM2ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/5074e94047bc8f0af85685e5b26bfc79","width":400,"height":209}},"href":"https://mma.prnewswire.com/media/2858641/Doseology_Sciences_Inc_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Doseology is focused on developing precision-controlled oral delivery systems within the emerging oral stimulant category. Guided by harm-reduction-oriented design principles, the Company aims to improve predictability and control in innovative consumer stimulant formats. As an early-stage platform company, Doseology is intentionally building its foundation—covering governance, intellectual property, and repeatable delivery systems—prior to scaling commercialization and broader growth initiatives.","length":502,"tagName":"p"},{"type":"text","content":"The appointment of Mr. Latowsky reflects the Company's confidence in both the timing of the category and the capability of its team to execute. His extensive experience operating at the intersection of public markets, institutional-scale enterprises, and regulated consumer health businesses is expected to strengthen Doseology's governance, capital-markets strategy, and overall strategic decision-making as it advances from early innovation toward broader commercialization.","length":484,"tagName":"p"},{"type":"text","content":"In connection with his appointment, the Company has granted Mr. Latowsky 4,000 restricted share units ("RSUs") and 6,000 performance share units ("PSUs"). Th...